Business
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately. “I am thrilled to welcome Ramón to the leadership team at Aligos,” said Sushmita Chanda, PhD, DABT, Execu
About this update from Aligos Therapeutics, Inc.
[{"type":"image","alt":"Aligos Therapeutics","displaySize":"","headline":null,"caption":"Aligos Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L8133ghONMF7WN.yZV6tsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955","width":150,"height":50}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately.","length":394,"tagName":"p"},{"type":"text","content":"“I am thrilled to welcome Ramón to the leadership team at Aligos,” said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. “As we progress ALG-000184 through the Phase 2 B-SUPREME study, Ramón’s extensive regulatory expertise will be a critical component as we think about the future of the program. His experience driving global regulatory strategies will help guide Aligos at this pivotal time.”","length":437,"tagName":"p"},{"type":"text","content":"“I am excited to join the Aligos team as the company looks towards later-stage development,” stated Ramón Polo, MBA, PharmD, PhD, Senior Vice President, Head of Global Regulatory Affairs at Aligos. “With my expertise leading global development and regulatory strategies at various pharma companies, I look forward to developing and implementing a comprehensive plan to aid in the continued development of ALG-000184.”","length":417,"tagName":"p"},{"type":"text","content":"Dr. Polo’s diverse expertise includes leading and overseeing development teams, pharmacovigilance programs and regulatory strategies. He joins Aligos from Shionogi Inc., where he served as the Senior Vice President, Head of Global Regulatory Affairs, and focused on regulatory strategies for a number of different Therapeutic Areas, including infectious diseases. Previously, Dr. Polo was the Vice President, Head of Infectiou...